Evidence map›Paper›PMID 25678559›Full record

ArticleBrain : a journal of neurology2015

Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.

Willem Huijbers, Elizabeth C Mormino, Aaron P Schultz, Sarah Wigman, Andrew M Ward, Mykol Larvie, Rebecca E Amariglio, Gad A Marshall, Dorene M Rentz, Keith A Johnson and 1 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04004702 (Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial), which is not on this map. Cited by 152 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 1 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04004702 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study

TypeinterventionalSponsorWalter Reed National Military Medical CenterRan2020 to 2025Enrolled65ConditionsAlzheimer DiseaseArmsLevetiracetam
3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 1 synthesis or guideline pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  8. Article
  9. Review
  10. Deep Learning-Based Prediction of PET Amyloid Status Using MRI.AJNR. American journal of neuroradiology · 2025
    Article
  11. Dosimetry and kinetic modelling of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Inhibition of the GSK3β/Nav1.6 complex suppresses early-stage Alzheimer's hyperexcitability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Willem Huijbers1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA w.huijbers@gmail.com.
Elizabeth C Mormino1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Aaron P Schultz3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sarah Wigman1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Andrew M Ward1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 4 Helen Willis Neuroscience Institute, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
Mykol Larvie2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rebecca E Amariglio1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Gad A Marshall1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Dorene M Rentz1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Keith A Johnson2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Reisa A Sperling1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital · USAthinoula A. Martinos Center for Biomedical Imaging · USBrigham and Women's Hospital · USHarvard University · US

Funding

Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Keith A. Johnson · 2010 to 2026
$50.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BETENSKY, REBECCA A. · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Project 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8M
Evolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6M
Mentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4M
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and ADK23AG033634 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI MARSHALL, GAD ASHER · 2009 to 2013
$727k
Deficits in top-down processes during episodic memory in aging and preclinical ADF32AG044054 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MORMINO, ELIZABETH · 2012 to 2014
$101k
NIA NIH HHS F32 AG044054NIA NIH HHS K23 AG033634NIA NIH HHS K24 AG035007NIA NIH HHS P01AG036694NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS P50AG00513421NIA NIH HHS R01 AG027435NIBIB NIH HHS P41EB015896
6 · The paper itself

Abstract

Cross-sectional functional magnetic resonance imaging studies using a memory task in patients with mild cognitive impairment have produced discordant results, with some studies reporting increased hippocampal activity--consistent with findings in genetic at-risk populations--and other studies reporting decreased hippocampal activity, relative to normal controls. However, previous studies in mild cognitive impairment have not included markers of amyloid-β, which may be particularly important in prediction of progression along the Alzheimer's disease continuum. Here, we examine the contribution of amyloid-β deposition to cross-sectional and longitudinal measures of hippocampal functional magnetic resonance imaging activity, hippocampal volume, global cognition and clinical progression over 36 months in 33 patients with mild cognitive impairment. Amyloid-β status was examined with positron emission tomography imaging using Pittsburg compound-B, hippocampal functional magnetic resonance imaging activity was assessed using an associative face-name memory encoding task, and hippocampal volume was quantified with structural magnetic resonance imaging. Finally global cognition was assessed using the Mini-Mental State Examination and clinical progression was assessed using the Clinical Dementia Rating (Sum of Boxes). At baseline, amyloid-β positive patients with mild cognitive impairment showed increased hippocampal activation, smaller hippocampal volumes, and a trend towards lower Mini-Mental State Examination scores and higher Clinical Dementia Ratings compared to amyloid-β negative patients with mild cognitive impairment. Longitudinally, amyloid-β positive patients with mild cognitive impairment continued to show high levels of hippocampal activity, despite increasing rates of hippocampal atrophy, decline on the Mini-Mental State Examination and faster progression on the Clinical Dementia Ratings. When entered simultaneously into the same linear mixed model, amyloid-β status, hippocampal activation, and hippocampal volume independently predicted clinical progression. These results indicate that amyloid-β positive patients with mild cognitive impairment are more likely on a path towards Alzheimer's disease dementia than amyloid-β negative patients. Increased hippocampal activity is discussed in relation to neuronal compensation and/or amyloid-β induced excitoxicity.

Indexed as

AgedAmyloid beta-PeptidesAtrophyCognitive DysfunctionCross-Sectional StudiesDisease ProgressionFemaleHippocampusHumansLongitudinal StudiesMagnetic Resonance ImagingMaleAmyloid beta-Peptidesamyloid depositionclinical progressionfunctional MRIhippocampal activationMCI

Identifiers

PMID25678559
PMCPMC4438387
OpenAlexW2153577700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.